CoChat
Sign Up
Cited by 65Cytokine Signaling Pathways and InteractionsMonoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment

Siltuximab (CNTO 328): a promising option for human malignancies

Open access
Chen, Bao-An, Chen, Runzhe·2015·Drug Design, Development and Therapy
DOI 10.2147/dddt.s86438PMC PMC4494175
Open this paper in CoChat — free accountOpen PDF

Abstract

Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 (IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of siltuximab in the treatment of human malignancies. We also provide our recommendations for siltuximab treatment in the future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s86438

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Siltuximab, a neutralizing anti-IL-6 monoclonal antibody, is being tested in various oncological settings.

    “Siltuximab, a neutralizing anti- IL-6 monoclonal antibody approved for the treatment of multicentric Castleman disease, is being tested in various oncological settings 225 .”

    From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [225]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. [1]Markham A Patel T Siltuximab: first global approval Drugs 2014 74 10 1147 1152 24958337
  2. [2]Bower M Stebbing J Exploiting interleukin 6 in multicentric Castleman’s disease Lancet Oncol 2014 15 9 910 912 25042200
  3. [3]Reichert JM Antibodies to watch in 2014: mid-year update MAbs 2014 6 4 799 802 24846335 PMC7098596
  4. [4]Bagcchi S Siltuximab in transplant-ineligible patients with myeloma Lancet Oncol 2014 15 8 e309 25121174
  5. [5]Barquero N Siltuximab: a new option for the management of Castleman’s disease Drugs Today (Barc) 2015 51 1 21 28 25685858
  6. [6]Stone RL Nick AM McNeish IA Paraneoplastic thrombocytosis in ovarian cancer N Engl J Med 2012 366 7 610 618 22335738 PMC3296780
  7. [7]Cavarretta IT Neuwirt H Zaki MH Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma Adv Exp Med Biol 2008 617 547 555 18497081
  8. [8]Song L Smith MA Doshi P Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer J Thorac Oncol 2014 9 7 974 982 24922005 PMC4057975
  9. [9]McCudden CR Voorhees PM Hainsworth SA Interference of monoclonal antibody therapies with serum protein electrophoresis tests Clin Chem 2010 56 12 1897 1899 20940329
  10. [10]Mayer CL Xie L Bandekar R Dose selection of siltuximab for multicentric Castleman’s disease Cancer Chemother Pharmacol 2015 75 5 1037 1045 10.1007/s00280-015-2720-0 25784388 · DOI
  11. [11]Liu YC Stone K van Rhee F Siltuximab for multicentric Castleman disease Expert Rev Hematol 2014 7 5 545 557 25110138
  12. [12]Chari A Pri-Chen H Jagannath S Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma Clin Lymphoma Myeloma Leuk 2013 13 3 333 337 23313067
  13. [13]Culig Z Cytokine disbalance in common human cancers Biochim Biophys Acta 2011 1813 2 308 314 21167870
  14. [14]Song L Rawal B Nemeth JA Haura EB JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling Mol Cancer Ther 2011 10 3 481 494 21216930 PMC4084653
  15. [16]Karkera J Steiner H Li W The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study Prostate 2011 71 13 1455 1465 21321981
  16. [17]Hunsucker SA Magarotto V Kuhn DJ Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma Br J Haematol 2011 152 5 579 592 21241278 PMC3402914
  17. [18]Voorhees PM Chen Q Small GW Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death Br J Haematol 2009 145 4 481 490 19344406 PMC3018832
  18. [19]Yao X Huang J Zhong H Targeting interleukin-6 in inflammatory autoimmune diseases and cancers Pharmacol Ther 2014 141 2 125 139 24076269
  19. [20]Coward J Kulbe H Chakravarty P Interleukin-6 as a therapeutic target in human ovarian cancer Clin Cancer Res 2011 17 18 6083 6096 21795409 PMC3182554
  20. [21]Soumerai JD Sohani AR Abramson JS Diagnosis and management of Castleman disease Cancer Control 2014 21 4 266 278 25310208
  21. [22]van Rhee F Fayad L Voorhees P Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease J Clin Oncol 2010 28 23 3701 3708 20625121
  22. [23]van Rhee F Wong RS Munshi N Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial Lancet Oncol 2014 15 9 966 974 25042199
  23. [24]Dispenzieri A Jacobus S Vesole DH Callandar N Fonseca R Greipp PR Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial Leukemia 2010 24 8 1406 1411 20535147 PMC2921007
  24. [25]Moreau P The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies Semin Hematol 2012 49 Suppl 1 S33 S46 22727391
  25. [26]de la Puente P Azab AK Contemporary drug therapies for multiple myeloma Drugs Today (Barc) 2013 49 9 563 573 24086952
  26. [27]Suzuki K Ogura M Abe Y Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma Int J Hematol 2015 101 3 286 294 25655379
  27. [28]Orlowski RZ Gercheva L Williams C A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma Am J Hematol 2015 90 1 42 49 25294016 PMC4737504
  28. [29]Voorhees PM Manges RF Sonneveld P A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma Br J Haematol 2013 161 3 357 366 23432640 PMC5837861
  29. [30]Bulycheva E Rauner M Medyouf H Myelodysplasia is in the niche: novel concepts and emerging therapies Leukemia 2015 29 2 259 268 25394715 PMC4320287
  30. [31]Garcia-Manero G Gartenberg G Steensma DP A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome Am J Hematol 2014 89 9 E156 E162 24888488
  31. [32]Angevin E Tabernero J Elez E A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors Clin Cancer Res 2014 20 8 2192 2204 24563479
  32. [33]Fizazi K De Bono JS Flechon A Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer Eur J Cancer 2012 48 1 85 93 22129890
  33. [34]Dorff TB Goldman B Pinski JK Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin Cancer Res 2010 16 11 3028 3034 20484019 PMC2898710
  34. [35]Rossi JF Negrier S James ND A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer Br J Cancer 2010 103 8 1154 1162 20808314 PMC2967052
  35. [36]van Rhee F Rothman M Ho KF Patient-reported outcomes for multicentric Castleman’s disease in a randomized, placebo-controlled study of siltuximab Patient 2015 8 2 207 216 25736164 PMC4383814
  36. [37]Deisseroth A Ko CW Nie L FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease Clin Cancer Res 2015 21 5 950 954 25601959
  37. [38]Thomas SK Suvorov A Noens L Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma Cancer Chemother Pharmacol 2014 73 1 35 42 24149943

Cited by

Sorted by citations

Authors
Chen, B.-A., & Chen, R.
Affiliations
Zhongda Hospital Southeast University (CN)
ORCID
Chen, Runzhe
Venue
Drug Design, Development and Therapy
Publisher
Informa UK Limited
Published
2015-07
Volume
9
Pages
3455
ISSN
1177-8881 (ISSN-L)
DOI
10.2147/dddt.s86438
PMC
PMC4494175
OpenAlex
W1802748958
Cited by
65
References
1
Citations by year
2026: 3 · 2025: 8 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 5 · 2018: 9 · 2017: 7 · 2016: 6 · 2015: 1
FWCI
0.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81170492, 81370673)
  • Government of Jiangsu Province (BL2014078)
Topics
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
siltuximab, antibody-drug conjugates, interleukin-6, IL-6 neutralization, cancer cell death, mechanism of action, clinical trials, adverse effects, hematologic malignancies, lymphoma
MeSH terms
Interleukin-6 Inhibitors, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Neoplasms, Interleukin-6, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review